Molly Henderson Sells 6,583 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $43,381.97. Following the transaction, the chief financial officer now directly owns 93,546 shares in the company, valued at approximately $616,468.14. The trade was a 6.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $10,328.00.

Phathom Pharmaceuticals Trading Up 2.6 %

PHAT traded up $0.18 during mid-day trading on Thursday, hitting $7.17. 649,136 shares of the stock were exchanged, compared to its average volume of 943,045. The company has a market cap of $490.28 million, a PE ratio of -1.26 and a beta of 0.56. The firm’s fifty day moving average is $8.08 and its two-hundred day moving average is $12.53. Phathom Pharmaceuticals, Inc. has a 1-year low of $6.07 and a 1-year high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The business had revenue of $16.35 million during the quarter, compared to analyst estimates of $12.54 million. During the same quarter last year, the firm posted ($0.76) EPS. As a group, research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Huntington National Bank boosted its position in shares of Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after purchasing an additional 564 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Phathom Pharmaceuticals by 41.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after acquiring an additional 722 shares during the period. US Bancorp DE boosted its stake in shares of Phathom Pharmaceuticals by 28.6% during the 3rd quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after acquiring an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Phathom Pharmaceuticals by 10.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after acquiring an additional 1,339 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Phathom Pharmaceuticals in the 3rd quarter worth approximately $197,000. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.